Novartis receives first ever FDA approval for a CAR-T cell therapy, Kymriah(TM) (CTL019), for children and young adults with B-cell ALL that is refractory or has relapsed at least twice

World News: . []

Novartis International AG Novartis LINK  first ever FDA approval for a CAR-T cell therapy LINK  CTL019 for children and young LINK  with B-cell ALL that is refractory or has relapsed at least twice LINK  and transmitted by N asdaq C...

More news and information about Novartis International AG

Published By:

Thomson Reuters: 16:04 GMT Wednesday 30th August 2017

Published: .

Search for other references to "novartis" on SPi News


Share

Previous StoryNext Story

SPi News is published by Sector Publishing Intelligence Ltd.
© Sector Publishing Intelligence Ltd 2019. [Admin Only]
 
Sector Publishing Intelligence Ltd.
Agriculture House, Acland Road, DORCHESTER, Dorset DT1 1EF United Kingdom
Registered in England and Wales number 07519380.
 
Privacy Policy | Terms and Conditions | Contact Us